Press Release12

Vivacelle Biosciences said it will make its experimental sepsis treatment VBI-S available for compassionate use in COVID-19 patients. VBI-S is being investigated for treatment of decreased blood circulation due to…

CHICAGO--(BUSINESS WIRE)--Vivacelle Bio, Inc. today announces that the US. Food and Drug Administration (FDA) has granted it an Investigational New Drug (IND) clearance to proceed with its phase IIa clinical…